Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193,394,759
-
Total 13F shares
-
26,122,191
-
Share change
-
-159,572
-
Total reported value
-
$47,560,467
-
Put/Call ratio
-
0%
-
Price per share
-
$1.82
-
Number of holders
-
46
-
Value change
-
+$748,885
-
Number of buys
-
24
-
Number of sells
-
19
Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2020
As of 30 Jun 2020,
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,122,191 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, COWEN AND COMPANY, LLC, MORGAN STANLEY, VANGUARD GROUP INC, ADVISOR GROUP HOLDINGS, INC., GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, Hudson Bay Capital Management LP, PRIMECAP MANAGEMENT CO/CA/, and BANK OF MONTREAL /CAN/.
This page lists
46
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.